HOME / Notice / News / EN
NKCL Bio Group Inc. has signed MOA on April 27 with Qingdao Orthopedic Hospital (颐生健骨伤医院) , a hospital affiliated with China-TSRH Association in China, for business cooperation. In line with the social distancing, the MOA signing was held in the form of real-time video conference, and the numb...
NKCL Bio Group, a Korean bio-company that research and develops immune cell therapy, is attracting attention as a beneficiary company of ‘the Act on the Safety and Support of Advanced Regenerative Medicine and Advanced Bio-Pharmaceuticals' (hereinafter referred to as the Advanced Medicine Act). The ...
The Ministry of Food and Drug Safety and the Ministry of Health and Welfare announced on the 25th that the enactment of the Enforcement Decree of ‘The Act on the Safety and Support of Advanced Regenerative Medicine and Advanced Biopharmaceuticals' has passed the cabinet meeting. The Advanced Regener...
As a company that researches immune cell therapy using NK immune cells, NKCL Bio Group targets the $100 billion Immune cell therapy market through its differentiated technological competitiveness. It is leading the mass production and popularization of NK Immune Cell and products through a GMP certif...
NKCL Bio Group has won 2020 Korea Future Management Award in Promising Bio company category. Korea Future Management is to discover and honor the people, companies, and organizations who have outstanding competence in various section of the society, which is organized by The Korea Herald, and Herald ...